Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Role of locoregional therapies in the wake of systemic therapy.

Palmer DH, Malagari K, Kulik LM.

J Hepatol. 2020 Feb;72(2):277-287. doi: 10.1016/j.jhep.2019.09.023. Review.

PMID:
31954492
2.

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.

Elmetwali T, Salman A, Wei W, Hussain SA, Young LS, Palmer DH.

Sci Rep. 2020 Jan 15;10(1):342. doi: 10.1038/s41598-019-57293-y.

3.

A shared genetic basis of mimicry across swallowtail butterflies points to ancestral co-option of doublesex.

Palmer DH, Kronforst MR.

Nat Commun. 2020 Jan 3;11(1):6. doi: 10.1038/s41467-019-13859-y.

4.

Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.

Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ.

Future Oncol. 2020 Jan;16(1):4315-4325. doi: 10.2217/fon-2019-0658. Epub 2019 Dec 4.

5.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.

PMID:
31575541
6.

How to identify sex chromosomes and their turnover.

Palmer DH, Rogers TF, Dean R, Wright AE.

Mol Ecol. 2019 Nov;28(21):4709-4724. doi: 10.1111/mec.15245. Epub 2019 Oct 10.

7.

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ting Y, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Lerch MM, Mayerle J, Tjaden C, Strobel O, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer.

JAMA Surg. 2019 Sep 4. doi: 10.1001/jamasurg.2019.3337. [Epub ahead of print]

PMID:
31483448
8.

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group.

Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Erratum in: Lancet Oncol. 2019 Apr 2;:.

PMID:
30922733
9.

Chemotherapy for pancreatic cancer.

Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP.

Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. doi: 10.1016/j.lpm.2019.02.025. Epub 2019 Mar 15. Review.

PMID:
30879894
10.

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR.

Oncotarget. 2019 Jan 18;10(6):685. doi: 10.18632/oncotarget.26625. eCollection 2019 Jan 18.

11.

Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research.

Evans JP, Winiarski BK, Sutton PA, Ressel L, Duckworth CA, Pritchard DM, Palmer DH, Goldring CE, Kitteringham NR.

Lab Anim. 2019 Dec;53(6):598-609. doi: 10.1177/0023677219826165. Epub 2019 Feb 13.

12.

Experimental field tests of Batesian mimicry in the swallowtail butterfly Papilio polytes.

Palmer DH, Tan YQ, Finkbeiner SD, Briscoe AD, Monteiro A, Kronforst MR.

Ecol Evol. 2018 Jul 12;8(15):7657-7666. doi: 10.1002/ece3.4207. eCollection 2018 Aug.

13.

Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombroswki F, Weiss FU, Neoptolemos JP, Werner J, D'Haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Büchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J.

Gastroenterology. 2018 Nov;155(5):1625-1639.e2. doi: 10.1053/j.gastro.2018.08.009. Epub 2018 Aug 6.

PMID:
30092175
14.

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR.

Oncotarget. 2018 Jun 5;9(43):27104-27116. doi: 10.18632/oncotarget.25497. eCollection 2018 Jun 5. Erratum in: Oncotarget. 2019 Jan 18;10(6):685. Vicky, Fretwell L [corrected to Fretwell, Vicky L].

15.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

16.

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.

Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A, Schmid MC.

Cancer Res. 2018 Aug 1;78(15):4253-4269. doi: 10.1158/0008-5472.CAN-17-3876. Epub 2018 May 22.

17.

Therapeutic developments in pancreatic cancer: current and future perspectives.

Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH.

Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348. doi: 10.1038/s41575-018-0005-x. Review.

PMID:
29717230
18.

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T.

Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22.

19.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(8):1084-1088. doi: 10.1038/s41416-018-0005-1. Epub 2018 Mar 9.

20.

Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response.

Bowden DL, Sutton PA, Wall MA, Jithesh PV, Jenkins RE, Palmer DH, Goldring CE, Parsons JL, Park BK, Kitteringham NR, Vimalachandran D.

J Proteomics. 2018 May 15;179:53-60. doi: 10.1016/j.jprot.2018.02.030. Epub 2018 Mar 6.

PMID:
29518574
21.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(7):947-954. doi: 10.1038/s41416-018-0004-2. Epub 2018 Mar 8.

22.

Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.

Sutton PA, Jithesh PV, Jones RP, Evans JP, Vimalachandran D, Malik HZ, Park BK, Goldring CE, Palmer DH, Kitteringham NR.

Eur J Surg Oncol. 2018 Jan;44(1):115-121. doi: 10.1016/j.ejso.2017.10.211. Epub 2017 Nov 13.

PMID:
29174709
23.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer.

Ann Surg. 2019 Mar;269(3):520-529. doi: 10.1097/SLA.0000000000002557.

PMID:
29068800
24.

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.

Edeline J, Blanc JF, Campillo-Gimenez B, Ma YT, King J, Faluyi O, Mathurin J, Ghazi S, Palmer DH, Meyer T.

Eur J Cancer. 2017 Nov;86:135-142. doi: 10.1016/j.ejca.2017.08.036. Epub 2017 Oct 4.

PMID:
28987770
25.

Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.

Ma YT, Leonard SM, Gordon N, Anderton J, James C, Huen D, Woodman CB, Palmer DH.

Oncotarget. 2017 Jun 29;8(38):63635-63645. doi: 10.18632/oncotarget.18879. eCollection 2017 Sep 8.

26.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

27.

Beyond ESPAC-4: better surgery and systemic therapy.

Psarelli EE, Jackson R, Neoptolemos JP, Palmer DH, Ghaneh P, Halloran CM, Büchler MW.

Lancet. 2017 Apr 15;389(10078):1517-1518. doi: 10.1016/S0140-6736(17)30947-9. No abstract available.

PMID:
28422026
28.

Gene expression profiling in bladder cancer identifies potential therapeutic targets.

Hussain SA, Palmer DH, Syn WK, Sacco JJ, Greensmith RM, Elmetwali T, Aachi V, Lloyd BH, Jithesh PV, Arrand J, Barton D, Ansari J, Sibson DR, James ND.

Int J Oncol. 2017 Apr;50(4):1147-1159. doi: 10.3892/ijo.2017.3893. Epub 2017 Mar 2.

29.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP.

Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2.

PMID:
28259610
30.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.

31.

Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre.

Faluyi OO, Connor JL, Chatterjee M, Ikin C, Wong H, Palmer DH.

Br J Cancer. 2017 Feb 14;116(4):424-431. doi: 10.1038/bjc.2016.406. Epub 2017 Jan 12.

32.

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.

Liver Int. 2017 Jul;37(7):1047-1055. doi: 10.1111/liv.13359. Epub 2017 Feb 2.

PMID:
28066978
33.

Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.

King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, Darby S, Braconi C, Iwuji C, Swinson D, Collins P, Patel K, Nobes J, Muazzam I, Blesing C, Kirkwood A, Nash S, Meyer T.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):256-262. doi: 10.1016/j.clon.2016.11.012. Epub 2016 Dec 10.

PMID:
27964898
34.

A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.

Edeline J, Blanc JF, Johnson P, Campillo-Gimenez B, Ross P, Ma YT, King J, Hubner RA, Sumpter K, Darby S, Evans J, Iwuji C, Swinson D, Collins P, Patel K, Muazzam I, Palmer DH, Meyer T.

Liver Int. 2016 Dec;36(12):1821-1828. doi: 10.1111/liv.13170. Epub 2016 Jun 22.

PMID:
27214151
35.

NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism.

Elmetwali T, Salman A, Palmer DH.

Cell Death Dis. 2016 Mar 17;7:e2146. doi: 10.1038/cddis.2016.52.

36.

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.

Middleton G, Greenhalf W, Costello E, Shaw V, Cox T, Ghaneh P, Palmer DH, Neoptolemos JP.

Br J Cancer. 2016 Mar 1;114(5):510-8. doi: 10.1038/bjc.2015.468. Epub 2016 Feb 4.

37.

Randomized clinical trial of prehabilitation before planned liver resection.

Dunne DF, Jack S, Jones RP, Jones L, Lythgoe DT, Malik HZ, Poston GJ, Palmer DH, Fenwick SW.

Br J Surg. 2016 Apr;103(5):504-12. doi: 10.1002/bjs.10096. Epub 2016 Feb 11.

PMID:
26864728
38.

The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial.

Loughney L, West MA, Kemp GJ, Rossiter HB, Burke SM, Cox T, Barben CP, Mythen MG, Calverley P, Palmer DH, Grocott MP, Jack S.

Trials. 2016 Jan 13;17:24. doi: 10.1186/s13063-015-1149-4.

39.

Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort Study.

Edwards NC, Yuan M, Nolan O, Pawade TA, Oelofse T, Singh H, Mehrzad H, Zia Z, Geh JI, Palmer DH, May CJ, Ayuk J, Shah T, Rooney SJ, Steeds RP.

J Clin Endocrinol Metab. 2016 Jan;101(1):183-90. doi: 10.1210/jc.2015-3295. Epub 2015 Nov 18.

PMID:
26580239
40.

From mice to men: Murine models of colorectal cancer for use in translational research.

Evans JP, Sutton PA, Winiarski BK, Fenwick SW, Malik HZ, Vimalachandran D, Tweedle EM, Costello E, Palmer DH, Park BK, Kitteringham NR.

Crit Rev Oncol Hematol. 2016 Feb;98:94-105. doi: 10.1016/j.critrevonc.2015.10.009. Epub 2015 Nov 1. Review.

PMID:
26558688
41.

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.

Palmer DH, Johnson PJ.

Cancer Metastasis Rev. 2015 Sep;34(3):497-509. doi: 10.1007/s10555-015-9580-2. Review.

PMID:
26250585
42.

Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers.

Jones RP, Bird NT, Smith RA, Palmer DH, Fenwick SW, Poston GJ, Malik HZ.

Biomark Med. 2015;9(8):763-75. doi: 10.2217/BMM.15.48. Epub 2015 Jul 30. Review.

PMID:
26223884
43.

Divergence and gene flow among Darwin's finches: A genome-wide view of adaptive radiation driven by interspecies allele sharing.

Palmer DH, Kronforst MR.

Bioessays. 2015 Sep;37(9):968-74. doi: 10.1002/bies.201500047. Epub 2015 Jul 22. Review.

44.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

45.

Evaluation of a novel tissue stabilization gel to facilitate clinical sampling for translational research in surgical trials.

Sutton PA, Jones RP, Morrison F, Goldring CE, Park BK, Palmer DH, Malik HZ, Vimalachandran D, Kitteringham NR.

Br J Surg. 2015 Jan;102(2):e124-32. doi: 10.1002/bjs.9678.

PMID:
25627125
46.

Cardiopulmonary exercise testing before liver surgery.

Dunne DF, Jones RP, Lythgoe DT, Pilkington FJ, Palmer DH, Malik HZ, Poston GJ, Lacasia C, Jack S, Fenwick SW.

J Surg Oncol. 2014 Sep;110(4):439-44. doi: 10.1002/jso.23670. Epub 2014 Jun 4.

PMID:
24894657
47.

Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.

Elmetwali T, Young LS, Palmer DH.

Cell Death Dis. 2014 May 8;5:e1213. doi: 10.1038/cddis.2014.172.

48.

doublesex is a mimicry supergene.

Kunte K, Zhang W, Tenger-Trolander A, Palmer DH, Martin A, Reed RD, Mullen SP, Kronforst MR.

Nature. 2014 Mar 13;507(7491):229-32. doi: 10.1038/nature13112. Epub 2014 Mar 5.

PMID:
24598547
49.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW; European Study Group for Pancreatic Cancer.

J Natl Cancer Inst. 2014 Jan;106(1):djt347. doi: 10.1093/jnci/djt347. Epub 2013 Dec 3.

PMID:
24301456
50.

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.

Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, Ross PJ.

Br J Cancer. 2013 Aug 20;109(4):888-90. doi: 10.1038/bjc.2013.410. Epub 2013 Jul 23.

Supplemental Content

Loading ...
Support Center